Merz Pharma Gmbh & Co Kgaa

Chemisch Pharmazeutische Forschungsgesellschaft M.b.h.

Michael Pyerin

Herbert Koller

Dieter Binder

Markus Henrich

Josef Weinberger

Federico Sbrogiò

Markus-Rene Gold

Simona Negura

Gergely Tasi

Pal Kocsan

Pál KOCSÁN

Federico Sbrogió

The present invention pertains to process for the amidation of a substituted 1-bromo-adamantane comprising a step (0) of reacting a substituted adamantane with an excess of bromine to obtain a 1-bromo-adamantane and a step (i) of reacting said substituted 1-bromo-adamantane with an amide, wherein the substituted 1-bromo-adamantane is used in the form of a mixture comprising bromine as obtained in step (0), wherein in step (0) a bromine: substituted adamantane molar ratio of from [2.5:1] to less than [5:1] is employed.

Process for manufacturing adamantane derivatives with high yield

Process for manufacturing 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate comprising step (i):

Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate

Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane, an intermediate in the synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof, comprising step (iii):

Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane

Thienothiazine derivatives of the formula ##STR1## are provided. These derivatives are useful for the treatment of inflammation and pain.

Thienithiazine derivatives

Growing community of inventors

Brunn am Gebirge, Austria

Michael Pyerin